Regulatory News ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population July 18, 2025Vol.51 No.28By Jacquelyn Cobb and Sara Willa Ernst
Sponsored Imaging’s ride to the bottom in clinical trials—and why it matters now July 18, 2025Vol.51 No.28By Jeff Sorenson
Cancer Policy NIH says it’s moving away from animal-based models July 18, 2025Vol.51 No.28By Claire Marie Porter
Drugs & Targets FDA gives TAR-200 Priority Review for invasive bladder cancer July 18, 2025Vol.51 No.28
FreeIn the Archives Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology July 11, 2025Vol.51 No.27By Katie Goldberg
Cancer Policy In the name of “radical transparency,” FDA touts publication of 200 complete response letters July 11, 2025Vol.51 No.27By Jacquelyn Cobb
Drugs & Targets FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins July 03, 2025Vol.51 No.26
Drugs & Targets FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM July 03, 2025Vol.51 No.26
Drugs & Targets REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated July 03, 2025Vol.51 No.26
Cancer Policy Jacqueline Corrigan-Curay to retire as acting head of CDER at FDA June 27, 2025Vol.51 No.25By Claire Marie Porter
